<DOC>
	<DOCNO>NCT00769145</DOCNO>
	<brief_summary>The primary purpose trial evaluate safety tolerability ranibizumab give via subconjunctival injection patient undergoing corneal transplantation .</brief_summary>
	<brief_title>Ranibizumab Inhibition Neovascularization Cornea Following Corneal Transplant Surgery</brief_title>
	<detailed_description>As secondary objective , study also aim establish corneal anterior chamber concentration ranibizumab deliver subconjunctivally limbus patient undergo corneal transplantation . The effect ranibizumab corneal epithelial healing examine follow adjunctive use corneal transplantation . Finally , clinical characteristic include recurrent corneal neovascularization study .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Patient relate consideration All patient gender consider enrollment . Disease related consideration Patients meeting accept criterion undergo corneal transplantation consider peripheral corneal neovascularization exist 2 contiguous clock hour Subjects meet follow criterion exclude study : Pregnancy ( positive pregnancy test ) Women seek become pregnant Lactating woman Prior enrollment study Prior glaucoma surgery region corneal neovascularization Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Corneal neovascularization</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Corneal transplantation</keyword>
</DOC>